Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance.
Eleonora PalluzziClaudia MarchettiSerena CappuccioGiacomo AvesaniGabriella MacchiaMaria Antonietta GambacortaFabrizio CocciolilloGiovanni ScambiaAnna FagottiPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)
Patients with recurrent ovarian cancer who have oligometastic progression during PARPi maintenance may continue to benefit from PARPi if combined with local treatment.